Autologous blood transfusion using recombinant human erythropoietin in radical hysterectomy.
The possibility of serious complications of infection and GVHD and adverse prognosis in cancer patients resulting from homologous blood transfusions has been reported. We used recombinant human erythropoietin (rHuEPO) in autologous blood transfusions for radical hysterectomies to avoid the risks associated with transfusions. rHuEPO efficacy, stability and influence on hemodynamics were investigated. All patients were able to donate 1,200 ml of autologous blood prior to surgery, and anemia did not result despite phlebotomy three times each week. Elevation in Hb concentration was calculated at 0.78 +/- 0.37 g/dl over the first 7 days, and 2.12 +/- 0.35 g/dl over the first 14 days. No adverse side effects were observed in any patient. The serum EPO level was measured by RIA, and compared to the homologous blood transfusion group. rHuEPO did not influence postoperative EPO secretion. Autologous blood transfusion with rHuEPO in radical hysterectomy was extremely effective in mitigating the risks associated with homologous blood transfusions.
Yamawaki
T
T
Department of Obstetrics and Gynecology, Mie University School of Medicine, Japan.
Tanaka
H
H
Takeuchi
S
S
Yanase
H
H
Taniguchi
H
H
Toyoda
N
N
D001804:Blood Transfusion, Autologous / Q000379:methods*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007044:Hysterectomy; D011994:Recombinant Proteins / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000601:surgery*
D011994:Recombinant Proteins; D004921:Erythropoietin